Intuitive Surgical Stock Before Q3 2026 Earnings: Boston Scientific Shows How Rivals Take Share, and Where to Look

Intuitive Surgical reports its third quarter on Tuesday, October 20, after the close. At the October 16 close the stock had recovered a good part of what it lost after the July report, when it fell more than 11% the next morning on a beat because US da Vinci growth had slowed, and it was still about 30% under its January 2025 peak. I'm writing this before the print so the claims below can be checked against it.

Since July the stock has been argued about in terms of the rivals. TIKR put the summer drop down partly to Ottava, which it called the first credible challenger to da Vinci in two decades. On August 12 Oppenheimer upgraded the stock with a $500 target after field checks found workflow problems with Ottava and a large footprint with Hugo, and it concluded that US competition isn't a factor in Intuitive's growth. I think the rivals had nothing to do with the slowdown so far. But one of the other medtech leaders in our coverage has just lost US share to Medtronic and J&J, and how that happened says where to look at Intuitive.

BSX didn't lose its lead because a rival got cleared. Medtronic's PulseSelect was the first pulsed field ablation system the FDA approved, in December 2023, and Boston Scientific's Farapulse followed seven weeks later. Farapulse still became the leader, which Mahoney says it remains. The share shift came later, after Medtronic's Affera system and Sphere-9 catheter were approved in October 2024, a single catheter that maps the heart and ablates with either pulsed field or radiofrequency energy.

By July 2026, about 21 months after Sphere-9 was approved and two and a half years after the first rival was, Boston Scientific's US electrophysiology growth was down to 3% while Medtronic's was around 40%, in a quarter that had an extra week. I think what moved it was a rival product that labs wanted to try, and Sphere-9's timing fits, though Mahoney named no rival and J&J and Abbott were selling PFA systems too. What I'm surer of is how easy it was for labs to try one. An ablation catheter is chosen for each case. An electrophysiologist can use a Sphere-9 one week and a Farapulse the next, and the lab's decision is the sum of a lot of small ones. That's the part I think doesn't carry over to Intuitive, and it's why I don't think procedure growth is where a da Vinci share loss would show up first.

Both companies have regulatory lock-in rated strong, and Boston Scientific's case shows the limit of that rating. It describes the lag before a rival gets its own clearance, and in PFA there wasn't one, because the rivals were cleared alongside Farapulse. At Intuitive the lag is closing procedure by procedure. Hugo is cleared in urology and Medtronic filed in June for general surgery, including hernia, and gynecology. Ottava is cleared in ten general surgery procedures. The framework keeps Intuitive's rating strong and marks it as narrowing, with the narrowing ending only if those filings aren't cleared by the end of 2027. I'd go further and treat the lag as already gone wherever a rival is cleared, though that's my reading rather than the stock page's.

Two pillars differ between the two names. Learned interfaces is rated strong at Intuitive and intact at Boston Scientific, and the Boston Scientific note says retraining an electrophysiologist on a new catheter is measured in cases, enough to slow switching but not to prevent it. Network effects is rated weakened at Boston Scientific, with a note citing the US PFA share loss as proof that labs will switch, and intact at Intuitive, where surgeons who move hospitals pull da Vinci purchases with them. Those are both ratings of the same thing, the trained clinician, and the bigger difference behind them is how often the customer decides. A da Vinci is a capital purchase and its instruments only fit the console, so a hospital makes the switching decision once per system, when it replaces one or adds one.

None of the reasons management gave was a rival. The CFO named bariatric cases falling as more patients take GLP-1 drugs, a modest hit from patients losing enhanced ACA premium subsidies, and slightly slower growth in benign procedures, some of which can be put off. He also allowed that a business this size is running into the law of large numbers, and nobody on the call asked about Hugo or Ottava. Hugo was cleared only for urology, and Ottava wasn't cleared until three weeks after the quarter ended. I don't see a way for either robot to have moved a quarter of US procedure growth.

That's why LLY and NVO are in the scorecard below. They aren't part of the moat comparison. They're the demand side, the two drug makers whose GLP-1s are taking volume out of bariatric surgery, and they stand for the part of Tuesday's number that no moat in the framework protects against. A weak US procedure figure would mostly be about them and about insurance coverage. A strong one wouldn't clear the rivals either, because neither has had a full quarter of general surgery in the US.

The overlap with Intuitive's growth is narrower than the list of ten makes it look. Management named general surgery as the main US driver for 2026, and cholecystectomy and hernia repair as the high-volume procedures it's going after. Cholecystectomy is the one real overlap today. The big hernia procedures are inguinal and ventral, and Ottava is cleared only for hiatal hernia, with inguinal still in a trial. Hugo's general surgery filing, which includes hernia, is the clearance that would widen the overlap, and it could come at any time. Two of Ottava's cleared procedures, gastric bypass and sleeve, are bariatric, the category GLP-1s are shrinking.

In the second quarter Intuitive recorded 144 trade-in transactions, up from 83 a year earlier, mostly US customers upgrading to da Vinci 5, and about half of all US placements were trades. Each was a hospital at the point where it could have bought something else. In the second quarter that wasn't much of a test. A large hospital's general surgery program had no large-cap alternative. The small, privately held rivals cleared in the US, CMR's Versius and Distalmotion's Dexter, cover cholecystectomy and, for Dexter, inguinal hernia, and Hugo was cleared only for urology. From the third quarter on, with Ottava cleared and Hugo's general surgery filing pending, it starts to be one. If hospitals with a cleared alternative keep trading up to da Vinci 5, the surgeon lock is doing what the rating says. If trade-ins fall while procedures hold up, I'd read it as hospitals pausing to compare.

The objection a holder would raise first is that trade-ins follow the da Vinci 5 upgrade cycle, whatever the rivals do. The CFO said on the July call that the upgrade cycle is progressive and occurs over multiples of years, so trade-ins could level off or fall simply because the hospitals most eager to upgrade already have. If that happens, my test would read a maturing cycle as share loss. The way I'd tell them apart is the timing and what management says. A cycle should fade gradually while a large base of older systems is still in the field. A drop that arrives as Hugo's general surgery clearance lands, or alongside comments about longer sales cycles or competitive evaluations, would be the rivals. The procedure condition in the falsifiable claim is there for the same reason, so that weak demand alone doesn't trip it.

The strongest case against the thesis itself is that I'm leaning on the clinician, and Boston Scientific's history says not to. Electrophysiologists are highly trained specialists too, and Farapulse had the lead and the installed workflows when Sphere-9 arrived. Medtronic and J&J aren't start-ups. J&J's Ethicon business already sells staplers and energy devices into operating rooms, and a hospital that wants a second robot vendor for pricing leverage has a credible one for the first time. Ottava's table-integrated design is pitched at 30% to 50% less floor space, which matters in older operating rooms, and Needham expects J&J and Medtronic to take moderate US share. If a second vendor gets in through hospitals that don't yet own a da Vinci, or through an ambulatory surgery center, trade-ins would never show it, and my test would miss the share loss.

There's also a case that I'm watching the wrong rival. Oppenheimer sees the real competition in China, from domestic systems such as Medbot, Kangduo and Toumai, and management described increased domestic robotic competition and pricing pressure in China on the July call. That's a share fight already happening, in a market where Intuitive's placements are muted. I've left it out of the falsifiable claim because it doesn't tell us whether the surgeon lock holds in the US, but a reader who owns the stock for international growth should weight it more than I have.

The bullish version is that my test is too cautious. Oppenheimer's case rested partly on Intuitive's per-click model, which opens up lower-acuity ambulatory centers, and on customized price and volume contracts that make it hard for a rival to show a hospital a better return. US utilization per system still grew 3% in the second quarter. If the rivals never get past a few showcase hospitals, the trade-in line will look fine for years and the only thing that mattered for the stock was demand. In that case Tuesday is about GLP-1s and ACA coverage, and the competitive question can wait.

The ISRG scenario ladder in the scorecard sets out what the price has to believe. Its base case assumes procedure growth of 13% to 15% through 2027 and a steady upgrade cycle. That needs the demand side to hold and the rivals to stay small. I think the second is likelier than the first, for the reason in the matrix, but I wouldn't call either settled before Ottava has had a few quarters in US operating rooms.

I think Intuitive's regulatory lead is already gone wherever a rival is cleared, and Boston Scientific shows that a medtech lead can outlast the rivals' clearance by years and still give way once a rival product is good enough to try. What's left at Intuitive is the surgeon, the operating room team and the instruments that only fit the console, and I think those hold better than a catheter habit did. Tuesday will say more about demand than about any of that. The trade-in line over the next few quarters is where I'll find out whether I'm right.